Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.71 |
| ▸ | FNTB | P49356 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507286 | 0.88 | FNTA (0.87) | FNTAFNTBCYP3A4HSD17B10 | |
| SCHEMBL5758351 | 0.85 | FNTA (0.49) | FNTAFNTBCYP3A4CNR1KDM4E | |
| SCHEMBL5733786 | 0.83 | FNTA (1.00) | FNTAFNTBCYP3A4 | |
| SCHEMBL13186537 | 0.83 | FNTA (1.00) | FNTAFNTBCYP3A4 | |
| SCHEMBL5758174 | 0.83 | FNTA (0.47) | FNTAFNTBCYP3A4KDM4EMEN1 | |
| SCHEMBL5757517 | 0.83 | FNTA (0.49) | FNTAFNTBCYP3A4CNR1KDM4E | |
| SCHEMBL13573670 | 0.82 | FNTA (0.86) | FNTAFNTBCYP3A4 | |
| SCHEMBL11947187 | 0.82 | FNTA (0.74) | FNTAFNTBCYP3A4CNR1 | |
| SCHEMBL5756788 | 0.81 | CYP3A4 (0.70) | FNTAFNTBCYP3A4 | |
| SCHEMBL7141339 | 0.80 | FNTA (0.46) | FNTAFNTBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135769-A1 | Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives | ANGIBAUD PATRICK R | 2006-06-22 | — | — | US | disclosed |
| EP-1351954-B1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-05-03 | — | — | EP | disclosed |
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-08 | — | — | US | disclosed |
| EP-1351954-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002051834-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | FNTA, FNTB, ACAT2 | FNTA 1/4885FNTB 2/4885CYP3A4 100/4885 |
| US-20060135769-A1 | Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives | FNTA, FNTB, RABGGTB | FNTA 1/4885FNTB 2/4885CYP3A4 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.